MCID: ORP003
MIFTS: 59

Oropharynx Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for Oropharynx Cancer

MalaCards integrated aliases for Oropharynx Cancer:

Name: Oropharynx Cancer 12 15
Oropharyngeal Cancer 12 37 55 15
Malignant Neoplasm of Oropharynx 12 73
Oropharyngeal Carcinoma 12 73
Primary Malignant Neoplasm of Lateral Wall of Oropharynx 12
Malignant Neoplasm of Junctional Region of Oropharynx 12
Malignant Neoplasm of Posterior Wall of Oropharynx 12
Malignant Neoplasm of Lateral Wall of Oropharynx 12
Malignant Tumor of Posterior Wall of Oropharynx 12
Malignant Tumour of Mesopharynx 12
Malignant Oropharyngeal Tumor 12
Malignant Tumor of Oropharynx 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8557
NCIt 50 C7398
SNOMED-CT 68 93933005 93971002
KEGG 37 H01559

Summaries for Oropharynx Cancer

Disease Ontology : 12 A pharynx cancer that is located in the oropharynx.

MalaCards based summary : Oropharynx Cancer, also known as oropharyngeal cancer, is related to papilloma and squamous cell carcinoma. An important gene associated with Oropharynx Cancer is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Endometrial cancer and Glioma. The drugs Fluorouracil and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include tongue, tonsil and lymph node, and related phenotypes are Decreased viability in esophageal squamous lineage and homeostasis/metabolism

Wikipedia : 76 Oropharyngeal cancer is a disease in which cancer form in the tissues of the throat (oropharynx). The... more...

Related Diseases for Oropharynx Cancer

Diseases related to Oropharynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 263)
# Related Disease Score Top Affiliating Genes
1 papilloma 30.3 CCND1 CDKN2A KRT14 KRT5 KRT7 TP53
2 squamous cell carcinoma 29.7 CCND1 CDH1 CDKN2A EGFR TP53
3 tongue cancer 29.7 CCND1 CDH1 CDKN2A TP53
4 oral cavity cancer 29.5 CDH1 CRTC1 EGFR MAML2 TP53
5 squamous cell carcinoma, head and neck 29.4 CCND1 CDH1 CDKN2A EGFR TP53
6 nasopharyngeal carcinoma 29.4 CCND1 CDH1 CDKN2A EGFR TP53
7 adenocarcinoma 29.4 CCND1 CDH1 CDKN2A EGFR KIT TP53
8 lung cancer susceptibility 3 29.2 CCND1 CDH1 CDKN2A EGFR KRT7 TP53
9 cervical cancer 29.1 CCND1 CDH1 CDKN2A KRT14 KRT5 TP53
10 oropharyngeal cancer, childhood 12.2
11 cutaneous telangiectasia and cancer syndrome, familial 11.8
12 bladder squamous cell carcinoma 10.4 CDKN2A TP53
13 spitz nevus 10.3 CDKN2A TP53
14 optic nerve sheath meningioma 10.3 CDKN2A KRT5
15 jejunal cancer 10.3 KIT KRT7
16 intratubular embryonal carcinoma 10.3 KIT KRT7
17 vulvar intraepithelial neoplasia 10.3 KRT7 TP53
18 anaplastic oligodendroglioma 10.3 CDKN2A EGFR
19 malignant peritoneal mesothelioma 10.3 CDKN2A EGFR
20 cerebral convexity meningioma 10.3 CDH1 TP53
21 lacrimal system cancer 10.3 MAML2 NFIB
22 sensory organ benign neoplasm 10.3 KRT5 KRT7
23 balloon cell malignant melanoma 10.3 KRT5 KRT7
24 benign mesothelioma 10.3 KRT5 KRT7
25 bile duct mucoepidermoid carcinoma 10.3 KRT5 KRT7
26 middle ear adenoma 10.3 KRT5 KRT7
27 pleomorphic adenoma carcinoma 10.3 MAML2 TP53
28 esophageal adenosquamous carcinoma 10.3 CDH1 KRT5
29 breast cystic hypersecretory carcinoma 10.3 CDH1 KRT5
30 large intestine adenocarcinoma 10.3 CDH1 KRT7
31 linitis plastica 10.3 CDH1 KRT7
32 renal pelvis adenocarcinoma 10.3 CDH1 KRT7
33 adenoid squamous cell carcinoma 10.3 CDH1 KRT7
34 fibroepithelial basal cell carcinoma 10.3 KRT14 TP53
35 epiglottis neoplasm 10.3
36 vallecula cancer 10.3
37 squamous cell papilloma 10.3
38 epidermolysis bullosa simplex, autosomal recessive 1 10.3 KRT14 KRT5
39 cellular ependymoma 10.3 SMUG1 TP53
40 protoplasmic astrocytoma 10.3 SMUG1 TP53
41 colloid adenoma 10.3 SMUG1 TP53
42 bartholin's duct cyst 10.3 SMUG1 TP53
43 lichen planopilaris 10.2 KRT14 KRT5
44 tonsil squamous cell carcinoma 10.2 CCND1 CDKN2A
45 skin carcinoma in situ 10.2 CCND1 CDKN2A
46 bowenoid papulosis 10.2 CCND1 CDKN2A
47 renal cell carcinoma, papillary, 1 10.2 KIT KRT7 TP53
48 tongue squamous cell carcinoma 10.2 CDH1 CDKN2A TP53
49 malignant acrospiroma 10.2 KRT5 SMUG1
50 li-fraumeni syndrome 10.2 CDKN2A EGFR TP53

Comorbidity relations with Oropharynx Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Oropharynx Cancer:



Diseases related to Oropharynx Cancer

Symptoms & Phenotypes for Oropharynx Cancer

GenomeRNAi Phenotypes related to Oropharynx Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.32 ACCS CCND1 CD6 CDH1 CDKN2A KIT

MGI Mouse Phenotypes related to Oropharynx Cancer:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 ADH1C CCND1 CD6 CDH1 CDKN2A CRTC1
2 growth/size/body region MP:0005378 10.27 ADH1C CCND1 CDH1 CDKN2A CRTC1 EGFR
3 cellular MP:0005384 10.26 CCND1 CDH1 CDKN2A EGFR KIT KRT14
4 endocrine/exocrine gland MP:0005379 10.22 CCND1 CDH1 CDKN2A CRTC1 EGFR KIT
5 digestive/alimentary MP:0005381 10.15 CCND1 CDH1 CDKN2A EGFR KIT KRT14
6 immune system MP:0005387 10.14 CCND1 CD6 CDH1 CDKN2A CRTC1 EGFR
7 craniofacial MP:0005382 10.05 CCND1 EGFR KIT KRT14 KRT5 NFIB
8 integument MP:0010771 10.02 CCND1 CDH1 CDKN2A EGFR KIT KRT14
9 neoplasm MP:0002006 9.92 CCND1 CDH1 CDKN2A EGFR KIT KRT14
10 reproductive system MP:0005389 9.85 CCND1 CDH1 CDKN2A CRTC1 EGFR KIT
11 pigmentation MP:0001186 9.65 CDKN2A EGFR KIT KRT14 TP53
12 respiratory system MP:0005388 9.5 CCND1 CDKN2A EGFR KIT KRT14 NFIB
13 vision/eye MP:0005391 9.23 CCND1 CDKN2A EGFR KIT KRT14 NFIB

Drugs & Therapeutics for Oropharynx Cancer

Drugs for Oropharynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 363)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
2
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 15663-27-1 2767 441203 84093
3
Ethanol Approved Phase 4,Not Applicable 64-17-5 702
4
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
5
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
6
Nicotine Approved Phase 4,Phase 2,Phase 3,Not Applicable 54-11-5 942 89594
7 sodium fluoride Approved Phase 4 7681-49-4
8 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
9 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3
10 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
11 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
13 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Protective Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
15 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Antidepressive Agents Phase 4,Phase 3,Phase 2
17 Antidepressive Agents, Second-Generation Phase 4,Phase 2
18 Dopamine Uptake Inhibitors Phase 4,Phase 2
19 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
20 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
21 Dopamine Agents Phase 4,Phase 2
22 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2
23 Nicotinic Agonists Phase 4,Phase 2,Phase 3,Not Applicable
24 Cholinergic Agents Phase 4,Phase 2,Phase 3,Not Applicable
25 Central Nervous System Stimulants Phase 4,Phase 2,Phase 3,Not Applicable
26 Mitomycins Phase 4,Phase 3
27 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
28 Anti-Infective Agents, Local Phase 4,Not Applicable
29 Cariostatic Agents Phase 4
30 Fluorides Phase 4,Phase 1,Phase 2,Not Applicable
31 Listerine Phase 4
32
Ropivacaine Approved Phase 3 84057-95-4 175805 71273
33
Aldesleukin Approved Phase 3,Phase 2,Phase 1,Not Applicable 85898-30-2, 110942-02-4
34
Tegafur Approved, Investigational Phase 3,Phase 2 17902-23-7 5386
35
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816
36
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
37
Racepinephrine Approved Phase 3,Phase 2 329-65-7 838
38
Docetaxel Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1 114977-28-5 148124
39
Cetuximab Approved Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1,Not Applicable 205923-56-4 56842117 2333
40
Carboplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 38904 498142
41
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 33069-62-4 36314
42
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
43
Fluconazole Approved, Investigational Phase 2, Phase 3,Early Phase 1 86386-73-4 3365
44
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
45
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
46
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
47
Cobalt Approved, Experimental Phase 3,Phase 2 7440-48-4 104729
48
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
49
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
50
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 6006 143

Interventional clinical trials:

(show top 50) (show all 513)
# Name Status NCT ID Phase Drugs
1 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
2 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
3 Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer Recruiting NCT03691441 Phase 4 Chemotherapy
4 Essential Oils With and Without Alcohol: Substantivity and Antiplaque Effect Recruiting NCT03146390 Phase 4 Essential oils;Alcohol free essential oils
5 Analgesia of Fibula Free Flap Donor Site by Peri-Neuronal Catheter in Oro-Pharyngeal Carcinoma Surgery Unknown status NCT00181038 Phase 3
6 Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Advanced Cancer of the Oropharynx or Hypopharynx Unknown status NCT00003627 Phase 3 cisplatin;fluorouracil
7 Effects of the Bilateral Mandibular Nerve Block (V3) in Mandibular Osteotomy Unknown status NCT02618993 Phase 3
8 Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis. Unknown status NCT00964977 Phase 3
9 Brief Intraoperative Electrical Stimulation for Prevention of Shoulder Dysfunction After Oncologic Neck Dissection Unknown status NCT02268344 Phase 3
10 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
11 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
12 Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced Xerostomia Unknown status NCT00081029 Phase 3
13 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx Unknown status NCT00002702 Phase 3
14 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
15 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
16 Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Completed NCT01434394 Phase 2, Phase 3 Neo-adjuvant Erbitux-based chemotherapy
17 Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
18 Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Completed NCT00158652 Phase 3 5FU, Paraplatin
19 Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients Completed NCT01439724 Phase 3
20 Nicotine Lozenge or Tobacco-Free Snuff for Smokeless Tobacco Reduction Completed NCT01018394 Phase 2, Phase 3 nicotine lozenges;tobacco-free snuff
21 Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00008398 Phase 3
22 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
23 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
24 Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002507 Phase 3 mitomycin C;porfiromycin
25 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
26 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
27 Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx Completed NCT00004234 Phase 3
28 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
29 Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer Completed NCT00004917 Phase 3 cisplatin
30 Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00021125 Phase 3
31 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
32 Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT00771641 Phase 3
33 Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002888 Phase 3 cisplatin;fluorouracil;paclitaxel
34 Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery Completed NCT00002670 Phase 3 chemotherapy;cisplatin
35 Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00003809 Phase 3 cisplatin
36 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3 fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
37 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
38 Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00608205 Phase 3 cisplatin;fluorouracil
39 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00820248 Phase 3 cisplatin
40 Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00003328 Phase 3 porfiromycin
41 Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002654 Phase 3 chemotherapy;cisplatin
42 High-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002555 Phase 3 cisplatin
43 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003888 Phase 3 cisplatin;docetaxel;fluorouracil
44 Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer Completed NCT00006481 Phase 3 Biafine cream
45 Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00054561 Phase 3 isotretinoin
46 Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During Surgery Completed NCT00003576 Phase 3 cisplatin;fluorouracil
47 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
48 Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial) Completed NCT00095875 Phase 3 carboplatin;cisplatin;docetaxel;fluorouracil
49 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
50 Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer Recruiting NCT02908477 Phase 3 Docetaxel;Cisplatin

Search NIH Clinical Center for Oropharynx Cancer

Genetic Tests for Oropharynx Cancer

Anatomical Context for Oropharynx Cancer

MalaCards organs/tissues related to Oropharynx Cancer:

41
Tongue, Tonsil, Lymph Node, Testes, Prostate, Lung, Cervix

The Foundational Model of Anatomy Ontology organs/tissues related to Oropharynx Cancer:

19
The Oropharynx

Publications for Oropharynx Cancer

Articles related to Oropharynx Cancer:

(show top 50) (show all 1068)
# Title Authors Year
1
Comparison of psychosocial factors over time among HPV+ oropharyngeal cancer and tobacco-related oral cavity cancer patients. ( 30322742 )
2019
2
HPV-Associated Oropharyngeal Cancer in the HIV/AIDS Patient. ( 30523624 )
2019
3
The IL-1/IL-1R axis induces greater fibroblast-derived chemokine release in human papillomavirus-negative compared to positive oropharyngeal cancer. ( 30191960 )
2019
4
Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project. ( 29100700 )
2018
5
Treatment deintensification in human papillomavirus-positive oropharynx cancer: Outcomes from the National Cancer Data Base. ( 29243245 )
2018
6
Radiographic Imaging Does Not Reliably Predict Macroscopic Extranodal Extension in Human Papilloma Virus-Associated Oropharyngeal Cancer. ( 29969771 )
2018
7
Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer. ( 29948260 )
2018
8
Bayesian model and spatial analysis of oral and oropharynx cancer mortality in Minas Gerais, Brazil. ( 29267820 )
2018
9
Pitfalls of post-treatment PET after de-intensified chemoradiotherapy for HPV-associated oropharynx cancer: Secondary analysis of a phase 2 trial. ( 29496037 )
2018
10
Radiotherapy dose-volume parameters predict videofluoroscopy-detected dysphagia per DIGEST after IMRT for oropharyngeal cancer: Results of a prospective registry. ( 29961581 )
2018
11
Optimising volumetric arc radiotherapy for dental rehabilitation in oropharynx cancer - A retrospective dosimetry review and feasibility planning study. ( 29290281 )
2018
12
HPV status, like politics, is local-evaluating p16 staining and a new staging system in a Dutch cohort of oropharynx cancer. ( 29788169 )
2018
13
A prospective longitudinal assessment of MRI signal intensity kinetics of non-target muscles in patients with advanced stage oropharyngeal cancer in relationship to radiotherapy dose and post-treatment radiation-associated dysphagia: Preliminary findings from a randomized trial. ( 30206020 )
2018
14
Symptom Burden Associated With Late Lower Cranial Neuropathy in Long-term Oropharyngeal Cancer Survivors. ( 30193299 )
2018
15
Long-term analysis of transorally resected p16 + Oropharynx cancer: Outcomes and prognostic factors. ( 30152175 )
2018
16
Short- and Long-term Opioid Use in Patients with Oral and Oropharynx Cancer. ( 30396321 )
2018
17
Geographical Variation in Oral and Oropharynx Cancer Mortality in Brazil: A Bayesian Approach. ( 30477281 )
2018
18
Feasibility of Dose-escalated Hypofractionated Chemoradiation in Human Papilloma Virus-negative or Smoking-associated Oropharyngeal Cancer. ( 29478732 )
2018
19
Prognostic Significance of the Neutrophil/Lymphocyte Ratio in Patients with Non-Human Papilloma Virus-Related Oropharyngeal Cancer: A Retrospective Cohort Study. ( 30212829 )
2018
20
Transoral surgery (TOS) in oropharyngeal cancer: Different tools, a single mini-invasive philosophy. ( 30449487 )
2018
21
HPV16 increases the number of migratory cancer stem cells and modulates their miRNA expression profile in oropharyngeal cancer. ( 29663357 )
2018
22
HPV-relatedness definitions for classifying HPV-related oropharyngeal cancer patient do impact on TNM classification and patients' survival. ( 29664911 )
2018
23
Knowledge-based automated planning for oropharyngeal cancer. ( 29679492 )
2018
24
Speech-language therapy program for mouth opening in patients with oral and oropharyngeal cancer undergoing adjuvant radiotherapy: a pilot study. ( 29694489 )
2018
25
Multi-criteria optimization achieves superior normal tissue sparing in intensity-modulated radiation therapy for oropharyngeal cancer patients. ( 29706191 )
2018
26
Baseline Cognition Assessment Among Patients With Oropharyngeal Cancer Using PROMIS and NIH Toolbox. ( 29710116 )
2018
27
Identification of Malignancy-Associated Changes in Histologically Normal Tumor-Adjacent Epithelium of Patients with HPV-Positive Oropharyngeal Cancer. ( 29713583 )
2018
28
Transoral robotic surgery for oropharyngeal cancer: patient selection and special considerations. ( 29719420 )
2018
29
Revisiting vascular contraindications for transoral robotic surgery for oropharyngeal cancer. ( 29721545 )
2018
30
Response to ASTRO consensus guideline for oropharyngeal cancer: In Regard to Walker et al. ( 29724403 )
2018
31
Quality of life in oropharyngeal cancer: a structured review of the literature. ( 29725802 )
2018
32
Routine Adaptive Replanning of p16-Positive Stage N2b Oropharyngeal Cancer: Quality Improvement or Waste of Time? ( 29727312 )
2018
33
Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation. ( 29735186 )
2018
34
Health-related quality of life in oropharyngeal cancer survivors - a population-based study. ( 29748448 )
2018
35
Tumor volume as a prognostic marker in p16-positive and p16-negative oropharyngeal cancer patients treated with definitive intensity-modulated radiotherapy. ( 29774396 )
2018
36
Early Response Assessment on Mid-treatment Computed Tomography Predicts for Locoregional Recurrence in Oropharyngeal Cancer Patients Treated With Definitive Radiation Therapy. ( 29779936 )
2018
37
Development and external validation of nomograms in oropharyngeal cancer patients with known HPV-DNA status: a European Multicentre Study (OroGrams). ( 29795309 )
2018
38
Impact of HPV-associated p16-expression and other clinical factors on therapeutic decision-making in patients with oropharyngeal cancer: A GETTEC multicentric study. ( 29871820 )
2018
39
Predictors of oropharyngeal cancer survival in Europe. ( 29884419 )
2018
40
Human Papillomavirus and Oropharyngeal Cancer Among Indigenous Australians: Protocol for a Prevalence Study of Oral-Related Human Papillomavirus and Cost-Effectiveness of Prevention. ( 29884604 )
2018
41
Oral and oropharyngeal cancer: epidemiology and survival analysis. ( 29898090 )
2018
42
Biomarkers for early identification of recurrences in HPV-driven oropharyngeal cancer. ( 29909884 )
2018
43
National treatment times in oropharyngeal cancer treated with primary radiation or chemoradiation. ( 29909886 )
2018
44
AJCC-8ed nodal staging does not predict outcomes in surgically managed HPV-associated oropharyngeal cancer. ( 29909888 )
2018
45
College Students' Knowledge Concerning Oropharyngeal Cancer, Human Papillomavirus, and Intent Toward Being Examined. ( 29933253 )
2018
46
Human papillomavirus 16 E6 modulates the expression of miR-496 in oropharyngeal cancer. ( 29935424 )
2018
47
Relationship Between p16 Expression and Prognosis in Patients with Oropharyngeal Cancer Undergoing Surgery. ( 29936482 )
2018
48
Assessing Novel Drugs and Radiation Technology in the Chemoradiation of Oropharyngeal Cancer. ( 29954154 )
2018
49
Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer. ( 29960060 )
2018
50
Patients with early-stage oropharyngeal cancer can be identified with label-free serum proteomics. ( 29961760 )
2018

Variations for Oropharynx Cancer

Expression for Oropharynx Cancer

Search GEO for disease gene expression data for Oropharynx Cancer.

Pathways for Oropharynx Cancer

Pathways related to Oropharynx Cancer according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.59 CCND1 CDH1 CDKN2A EGFR KIT TP53
2
Show member pathways
12.56 CCND1 CDH1 CDKN2A EGFR TP53
3 12.52 CCND1 CDH1 CDKN2A EGFR KIT TP53
4 12.33 CCND1 CDKN2A EGFR TP53
5
Show member pathways
12.3 CCND1 CDH1 CDKN2A EGFR KIT TP53
6
Show member pathways
12.26 CCND1 CDKN2A EGFR KIT
7 12.24 CCND1 CDKN2A CRTC1 TP53
8 12.17 CCND1 CDH1 CDKN2A TP53
9 11.95 CCND1 CDH1 EGFR TP53
10 11.89 CCND1 CDH1 EGFR TP53
11 11.61 KRT14 KRT5 TP53
12 11.6 CCND1 CDKN2A EGFR TP53
13 11.47 MYBL1 NFIB TP53
14 11.45 EGFR KIT TP53
15 10.96 CCND1 CDKN2A EGFR TP53
16 10.96 CCND1 CDH1 CDKN2A EGFR TP53 TYMP

GO Terms for Oropharynx Cancer

Cellular components related to Oropharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 keratin filament GO:0045095 8.8 KRT14 KRT5 KRT7

Biological processes related to Oropharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 replicative senescence GO:0090399 9.43 CDKN2A TP53
2 hemidesmosome assembly GO:0031581 9.4 KRT14 KRT5
3 tongue development GO:0043586 9.37 EGFR KIT
4 somatic stem cell division GO:0048103 9.32 CDKN2A KIT
5 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.26 EGFR TP53
6 positive regulation of transcription by RNA polymerase II GO:0045944 9.23 CDKN2A CRTC1 EGFR MAML2 MYBL1 NFIB
7 mitotic G1 DNA damage checkpoint GO:0031571 9.16 CCND1 TP53
8 response to UV-A GO:0070141 8.96 CCND1 EGFR

Sources for Oropharynx Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....